OCREVUS Comprehensive Forecast on the Accelerating Market Growth for Multiple Sclerosis by 2034

AI Briefing

• – OCREVUS to become a first-line treatment for relapsing forms of multiple sclerosis by 2025, with a projected market size of $3.4 billion by 2034.
• – The market growth is driven by increasing prevalence of multiple sclerosis, growing awareness among patients and physicians, and expanding healthcare access in developed and emerging markets.
• – Key players including Biogen, Genentech, and Ionis Pharmaceuticals are expected to be major beneficiaries of the growing demand for OCREVUS.